Lumos Diagnostics Holdings Ltd
ASX:LDX
Lumos Diagnostics Holdings Ltd
Research & Development
Lumos Diagnostics Holdings Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lumos Diagnostics Holdings Ltd
ASX:LDX
|
Research & Development
-$106k
|
CAGR 3-Years
57%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Nanosonics Ltd
ASX:NAN
|
Research & Development
-AU$33.7m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Polynovo Ltd
ASX:PNV
|
Research & Development
-AU$5.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-17%
|
|
|
SDI Ltd
ASX:SDI
|
Research & Development
-AU$1.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-12%
|
|
|
Ansell Ltd
ASX:ANN
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Next Science Ltd
ASX:NXS
|
Research & Development
-$5m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
Lumos Diagnostics Holdings Ltd
Glance View
Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.
See Also
What is Lumos Diagnostics Holdings Ltd's Research & Development?
Research & Development
-106k
USD
Based on the financial report for Jun 30, 2025, Lumos Diagnostics Holdings Ltd's Research & Development amounts to -106k USD.
What is Lumos Diagnostics Holdings Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
44%
Over the last year, the Research & Development growth was -54%. The average annual Research & Development growth rates for Lumos Diagnostics Holdings Ltd have been 57% over the past three years , 44% over the past five years .
